Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Poster Abstract PresentationsSession Title: Angiotensin Action and Signaling/Renin Angiotensin System 2

Abstract P630: Captopril Reduces Cytopathic Effects in Herpes Simplex Virus 1 (HSV-1) Infected SH-SY5Y Cells

Amina Wofford, Justin Merritt, Cynthia Ann Jackson, Chastity N Bradford, Gerald Griffin
Hypertension. 2015;66:AP630
Amina Wofford
Tuskegee Univ, Tuskegee Institute, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Merritt
Tuskegee Univ, Tuskegee Institute, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Ann Jackson
Alabama A&M Univ, Normal, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chastity N Bradford
Tuskegee Univ, Tuskegee Institute, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald Griffin
Tuskegee Univ, Tuskegee Institute, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
  • Info & Metrics
  • eLetters
Loading

Abstract

Over 60% of the United States population is infected with HSV-1, a double-stranded DNA virus belonging to the Herpesviridae family. HSV-1 is continually documented as a leading infectious cause of corneal blindness and encephalitis. Members of the herpesviridae family have been implicated as cardiovascular pathogens and are independently associated with the future risk of cardiovascular death. Investigations have demonstrated that hypertension may be significantly related to inflammation, a major symptom of HSV-1 infection. Most HSV-1 antivirals are nucleoside analogs which are effective for individuals experiencing current outbreaks, but are limited by the development of antiviral resistance. Thus, there is a need for novel antiviral targets to decrease viral reactivation, a major player in viral associated neuropathologies. In addition to its well-known function of maintaining homeostatic control of arterial and osmotic pressure, components of the Renin Angiotensin System (RAS) have been demonstrated to exert antiviral functions. RAS targets, such as angiotensin peptides and angiotensin type 1 receptors, have been evaluated for their antiviral properties. Yet, the antiviral properties of other currently approved RAS inhibitors have not been investigated. To determine if other RAS components may inhibit viral activity, we tested the hypothesis that captopril, an inhibitor of angiotensin converting enzyme 1 (ACE), attenuates cytopathic effects of HSV-1 in SH-SY5Y, human neuroblastoma, cells. Photomicrographs of SH-SY5Y cells demonstrated that captopril protects cells from HSV-1-induced cytopathic effects. Additionally, cell viability assays revealed that captopril reduced HSV-1-induced cellular death by 18% (p-value<.05, compared to vehicle treated HSV-1 infected cells). Preliminary viral entry assay data suggests captopril may exert antiviral effects through entry inhibition as demonstrated by a 14.18% decrease in GFP immunofluorescence after captopril-treated cells were exposed to a GFP-expressing HSV-1 recombinant virus for 48h (compared to their untreated, uninfected counterparts). These results support captopril as a therapeutic target for the treatment of HSV-1 and its associated pathologies.

  • ACE inhibitor
  • Viruses
  • Hypertension
  • Author Disclosures: A. Wofford: None. J. Merritt: None. C. Jackson: None. C.N. Bradford: None. G. Griffin: None.

  • © 2015 by American Heart Association, Inc.
Back to top
Previous Article

This Issue

Hypertension
September 2015, Volume 66, Issue Suppl 1
  • Table of Contents
Previous Article

Jump to

  • Article
  • Info & Metrics

Article Tools

  • Citation Tools
    Abstract P630: Captopril Reduces Cytopathic Effects in Herpes Simplex Virus 1 (HSV-1) Infected SH-SY5Y Cells
    Amina Wofford, Justin Merritt, Cynthia Ann Jackson, Chastity N Bradford and Gerald Griffin
    Hypertension. 2015;66:AP630, originally published November 3, 2015

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Abstract P630: Captopril Reduces Cytopathic Effects in Herpes Simplex Virus 1 (HSV-1) Infected SH-SY5Y Cells
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Abstract P630: Captopril Reduces Cytopathic Effects in Herpes Simplex Virus 1 (HSV-1) Infected SH-SY5Y Cells
    Amina Wofford, Justin Merritt, Cynthia Ann Jackson, Chastity N Bradford and Gerald Griffin
    Hypertension. 2015;66:AP630, originally published November 3, 2015
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured